Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13484526 | 0.88 | MIF (0.46) | GABRA1GABRB2MIFESR1ESR2 | |
| SCHEMBL9821858 | 0.85 | ESR1 (0.51) | ESR1ESR2 | |
| SCHEMBL31562259 | 0.84 | CYP4F2 (0.49) | GABRA1GABRB2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL13903616 | 0.84 | GLS (0.40) | MIFALDH1A1MAPT | |
| SCHEMBL27390804 | 0.81 | SMN1; SMN2 (0.46) | GABRA1GABRB2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL5846867 | 0.80 | HPGD (0.54) | GABRA1GABRB2 | |
| SCHEMBL3519014 | 0.80 | HPGD (0.54) | GABRA1GABRB2 | |
| SCHEMBL5846876 | 0.80 | HPGD (0.54) | GABRA1GABRB2 | |
| SCHEMBL27719180 | 0.79 | L3MBTL1 (0.46) | MIFKDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL14518820 | 0.78 | CXCR1 (0.37) | GABRA1GABRB2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | GABRA1 3030/4885GABRB2 2959/4885MIF 3490/4885 |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | FAP, APC, VHL | GABRA1 3030/4885GABRB2 2959/4885MIF 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.